Aeolus Pharmaceuticals (AOLS) Inactive 10-K2007 FY Annual report

Filed: 13 Dec 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: acetate, Add, added, adult, agency, ailment, aimed, alkylating, antagonist, astrocyte, authentic, Avicena, bleeding, blister, blistering, carcinogenic, casualty, catalase, CDC, Cereact, cisplatin, color, comprehensive, conducing, contacted, Convention, CounterACT, countermeasure, cyanide, cytotoxic, deep, derecognition, dermal, detection, disaster, Edaravone, edema, Eisai, eleven, ethyl, Excellence, excitatory, fatal, fibrotic, Forest, forgave, garlic, gas, glatiramer, glutamate, horseradish, hour, hydrochloride, identification, instrument, itching, leadership, linked, Lundbeck, membrane, mimic, mitigate, mustard, nerve, network, odor, ovarian, overarching, Peking, pilocarpine, prescribing, pure, radioprotector, receptor, reinvestment, rescue, resembling, resurgence, room, Salagen, sc, Schwarz, smoother, SNS, sore, source, Stockpile, strongly, sulfide, sulfur, surface, swollen, Talampanel, Tanabe, temperature, terrorism, terrorist, Teva, thalidomide, theory, threat, threshold, trail, transportation, unilaterally, vesicant, warfare

Removed: announced, appointment, assumed, auditing, author, book, Carolina, chairman, classified, consult, contingently, Cranbury, decision, deem, default, deligoparin, disagreement, discount, entitle, examine, exchanged, executed, faculty, formed, immunology, Incara, investigator, IRL, Jersey, justify, leased, lymphatic, lymphoma, mature, Misha, noncash, North, owed, Park, payroll, Petkevich, procedure, recommended, redeemed, rendered, reportable, resigned, resolved, restricted, scope, sentence, sought, sublease, subsequent, Thornton, transferred, Triangle, ulcerative, utilized, wrote

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

AOLS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Annual Report of Aeolus Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ending September 30, 2007, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, John L. McManus, Principal Executive Officer of the Company, and Michael P. McManus, Principal Financial and Accounting Officer of the Company, each certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: December 13, 2007

__/s/ John L. McManus_______

John L. McManus

President and Chief Executive Officer

(Principal Executive Officer)

Date: December 13, 2007

__/s/ Michael P. McManus_____________

Michael P. McManus

Chief Financial Officer, Treasurer and Secretary

(Principal Financial and Accounting Officer)

THIS CERTIFICATION “ACCOMPANIES” THE ANNUAL REPORT, IS NOT DEEMED FILED WITH THE SEC AND IS NOT TO BE INCORPORATED BY REFERENCE INTO ANY FILING OF THE COMPANY UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (WHETHER MADE BEFORE OR AFTER THE DATE OF THE ANNUAL REPORT), IRRESPECTIVE OF ANY GENERAL INCORPORATION LANGUAGE CONTAINED IN SUCH FILING. A SIGNED ORIGINAL OF THIS CERTIFICATION HAS BEEN PROVIDED TO THE COMPANY AND WILL BE RETAINED BY THE COMPANY AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.